Lansdale, PA (PRWEB) May 7, 2010
Hayes Inc., the nation’s leading independent health technology research and consulting company, announces the release of two reports on first-of-a-kind technologies just approved by the Food and Drug Administration (FDA)—the Alair® Bronchial Thermoplasty System for medically refractory asthma, and the Provenge® prostate cancer vaccine for men with metastatic hormone-refractory disease. Hayes’ horizon scanning experts identified these emerging technologies more than 7 years ago as potential new options to address unmet treatment needs. Technology Prognosis, Hayes’ continuously updated horizon scanning service, has kept clients informed of every milestone leading to regulatory approval.
The Alair system for bronchial thermoplasty has potential to improve symptom control in adults with severe, medically refractory asthma, but the device and procedure have been evaluated in relatively few patients. The FDA based its approval on data from a clinical trial of 297 patients with severe and persistent asthma. The trial showed a reduction of severe asthma attacks with use of the Alair system. The FDA is requiring a 5-year postmarket study of the device to research its long-term safety and effectiveness.
Provenge is a vaccine given intravenously for the treatment of metastatic androgen-independent prostate cancer (AIPC), a grave condition with few treatment options. It does not prevent prostate cancer, and it is being evaluated only in patients already diagnosed with this disease. The vaccine appears to offer a modest but significant overall survival benefit in this patient subset but does not significantly delay the progression of the disease. Access to the vaccine may be limited initially by manufacturing capacity, as well as by cost concerns and issues of efficacy.
The Hayes Prognosis reports provide healthcare professionals with objective and unbiased information regarding these technologies, based on current evidence and expert analysis. The content includes the proposed clinical applications; relevant epidemiology and background information; an overview of anticipated costs, dissemination, and clinical setting requirements.
In addition, Hayes horizon scanning analysts offer conclusions and forecasts for anticipated adoption of these technologies. These insights provide hospitals, health insurers, and clinicians with guidance on appropriate technology applications, including patient selection and usage relative to existing clinical practice.
To learn more about Hayes Technology Prognosis, as well as purchase access to the Alair System and Provenge reports, contact us.
About Hayes, Inc.
Hayes, Inc. is an independent health technology research and consulting company dedicated to promoting better health outcomes through the use of evidence. Hayes performs unbiased, evidence-based healthcare technology assessments of the safety and efficacy of new, emerging, and controversial health technologies and evaluates the impact of these technologies on healthcare quality, utilization, and cost. Hayes’ worldwide clients include hospitals, healthcare systems, government agencies, employers, and managed care organizations. For more information, please visit http://www.hayesinc.com.